Longevity Fund

www.blg.vc

VCMatch tracks Longevity Fund as an investor focused on AI/ML, Biotech, and Medtech companies, Series B and Series C rounds, and Global markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Series B, Series C, Growth, Late Stage

Focus Areas

AI/ML, Biotech, Medtech

Geography

global

Investment Thesis

BOLD Longevity Growth applies a scientific, mission-driven investment philosophy focused on extending healthy human lifespan by funding frontier biotechnologies that address the root causes of aging and age-related disease. They prioritize platform technologies and growth-stage companies where scientific rigor, platform multiplicity, and demonstrable improvements in efficiency and safety can be scaled to make longevity innovations affordable and accessible.

Their approach is de-risked and outcome-oriented: they target companies that can deliver large step-change improvements (e.g., 5-10x efficiency/safety gains), seek relatively near-term liquidity (stating a 3-5 year to exit horizon), and co-invest alongside major biotech VC funds and big pharma to accelerate commercialization and adoption.

Is Longevity Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Longevity Fund is most relevant for founders raising Series B, Series C, and Growth rounds in AI/ML, Biotech, Medtech, and Digital Health, especially across global.

Focus statement

BOLD Longevity Growth focuses on growth-stage (Series B+) platform technologies at the intersection of longevity, biotech, and artificial intelligence, specifically targeting gene therapies & editing, cell therapies & regenerative medicine, AI drug discovery & early diagnostics, and AI-powered medtech & biosensing.

Value Add

Specialization in growth and scaling stages (Series B+), with an explicit 3-5 year target to exit.
Platform-first thesis ("Platform Tech (Multiple Assets)") seeking technologies that deliver >5-10x improvements in efficiency and safety.
Mission to make longevity technologies "affordable and accessible for everyone"—combining scientific and commercial objectives.
Co-investment strategy with the largest biotech VC funds and big pharma to accelerate scale and de-risk commercialization.
Team track record and prior investments showcasing large step-change outcomes (e.g., next-generation gene editing potentially 10x more efficient than CRISPR; AI-powered ultrasound 20-30x more affordable; AI cancer detection aiming to increase survival rates 6-7x).
Deep domain expertise supported by a scientific and venture advisory board that has collectively co-founded "more than 50+ biotech and longevity companies."